Cargando…
Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study
INTRODUCTION: In China, the long-term immunogenicity and adverse effects of inactivated vaccines produced by different or the same manufacturer remain unclear. Therefore, the objective of this study was to evaluate the cellular immune responses and neutralizing antibody kinetics of homologous and he...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020218/ https://www.ncbi.nlm.nih.gov/pubmed/36936962 http://dx.doi.org/10.3389/fimmu.2023.1107866 |
_version_ | 1784908205326860288 |
---|---|
author | Yuan, Youhua Xu, Junhong Ma, Bing Chen, Guohua Wang, Zhibin Wang, Shanmei Jing, Nan Zhang, Jiangfeng Wang, Baoya Yan, Wenjuan Zhang, Qi Zhao, Qiongrui Li, Yi |
author_facet | Yuan, Youhua Xu, Junhong Ma, Bing Chen, Guohua Wang, Zhibin Wang, Shanmei Jing, Nan Zhang, Jiangfeng Wang, Baoya Yan, Wenjuan Zhang, Qi Zhao, Qiongrui Li, Yi |
author_sort | Yuan, Youhua |
collection | PubMed |
description | INTRODUCTION: In China, the long-term immunogenicity and adverse effects of inactivated vaccines produced by different or the same manufacturer remain unclear. Therefore, the objective of this study was to evaluate the cellular immune responses and neutralizing antibody kinetics of homologous and heterologous administrations of an inactivated coronavirus disease 2019 (COVID-19) vaccine 240 days after the second vaccination. METHODS: This prospective, multicenter, observational, longitudinal study involved 595 participants with a negative SARS-CoV-2 polymerase chain reaction result who were serologically tested and followed for 8 months after vaccination. Neutralizing antibodies, interferon-gamma (IFN-γ), interleukin (IL)-6, CD4+ T-lymphocyte, and B-lymphocyte counts were evaluated in serum samples after stimulation with 2 μg/mL SARS-CoV-2 spike protein for 16 h at follow-up intervals of 2 months. RESULTS: Most participants [582/595; 146 male participants, 449 female participants; mean age 35 (26–50 years)] rapidly developed neutralizing antibodies after two doses of the vaccine administered 3-weeks apart. The positive rate of neutralizing antibodies peaked at 97.7% at 60–90 days, decreased, and stabilized at 82.9% at 181–240 days post-vaccination. Lower antibody concentrations were correlated with older age, longer duration after vaccination, non-health care workers, mixed-manufacturer vaccinations, and intervals of less than 40 days between two doses of vaccination, whereas lower IFN-γ levels and B-lymphocyte counts were associated with older age, blood type A, and non-health care workers. A higher IL-6 level was associated with older age, mixed-manufacturer vaccinations, intervals of less than 40 days between two doses of vaccination, and medical staff. Adverse reactions were mild or moderate and self-limited, with no serious events reported. DISCUSSION: Two doses of the Chinese inactivated vaccine induced robust and rapid antibody expression and cellular immune responses. Boosting vaccination is considered important, as antibodies and cellular immune responses were reduced in susceptible populations. |
format | Online Article Text |
id | pubmed-10020218 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100202182023-03-18 Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study Yuan, Youhua Xu, Junhong Ma, Bing Chen, Guohua Wang, Zhibin Wang, Shanmei Jing, Nan Zhang, Jiangfeng Wang, Baoya Yan, Wenjuan Zhang, Qi Zhao, Qiongrui Li, Yi Front Immunol Immunology INTRODUCTION: In China, the long-term immunogenicity and adverse effects of inactivated vaccines produced by different or the same manufacturer remain unclear. Therefore, the objective of this study was to evaluate the cellular immune responses and neutralizing antibody kinetics of homologous and heterologous administrations of an inactivated coronavirus disease 2019 (COVID-19) vaccine 240 days after the second vaccination. METHODS: This prospective, multicenter, observational, longitudinal study involved 595 participants with a negative SARS-CoV-2 polymerase chain reaction result who were serologically tested and followed for 8 months after vaccination. Neutralizing antibodies, interferon-gamma (IFN-γ), interleukin (IL)-6, CD4+ T-lymphocyte, and B-lymphocyte counts were evaluated in serum samples after stimulation with 2 μg/mL SARS-CoV-2 spike protein for 16 h at follow-up intervals of 2 months. RESULTS: Most participants [582/595; 146 male participants, 449 female participants; mean age 35 (26–50 years)] rapidly developed neutralizing antibodies after two doses of the vaccine administered 3-weeks apart. The positive rate of neutralizing antibodies peaked at 97.7% at 60–90 days, decreased, and stabilized at 82.9% at 181–240 days post-vaccination. Lower antibody concentrations were correlated with older age, longer duration after vaccination, non-health care workers, mixed-manufacturer vaccinations, and intervals of less than 40 days between two doses of vaccination, whereas lower IFN-γ levels and B-lymphocyte counts were associated with older age, blood type A, and non-health care workers. A higher IL-6 level was associated with older age, mixed-manufacturer vaccinations, intervals of less than 40 days between two doses of vaccination, and medical staff. Adverse reactions were mild or moderate and self-limited, with no serious events reported. DISCUSSION: Two doses of the Chinese inactivated vaccine induced robust and rapid antibody expression and cellular immune responses. Boosting vaccination is considered important, as antibodies and cellular immune responses were reduced in susceptible populations. Frontiers Media S.A. 2023-03-03 /pmc/articles/PMC10020218/ /pubmed/36936962 http://dx.doi.org/10.3389/fimmu.2023.1107866 Text en Copyright © 2023 Yuan, Xu, Ma, Chen, Wang, Wang, Jing, Zhang, Wang, Yan, Zhang, Zhao and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Yuan, Youhua Xu, Junhong Ma, Bing Chen, Guohua Wang, Zhibin Wang, Shanmei Jing, Nan Zhang, Jiangfeng Wang, Baoya Yan, Wenjuan Zhang, Qi Zhao, Qiongrui Li, Yi Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study |
title | Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study |
title_full | Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study |
title_fullStr | Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study |
title_full_unstemmed | Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study |
title_short | Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study |
title_sort | characteristics of humoral and cellular responses to coronavirus disease 2019 (covid-19) inactivated vaccine in central china: a prospective, multicenter, longitudinal study |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020218/ https://www.ncbi.nlm.nih.gov/pubmed/36936962 http://dx.doi.org/10.3389/fimmu.2023.1107866 |
work_keys_str_mv | AT yuanyouhua characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy AT xujunhong characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy AT mabing characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy AT chenguohua characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy AT wangzhibin characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy AT wangshanmei characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy AT jingnan characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy AT zhangjiangfeng characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy AT wangbaoya characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy AT yanwenjuan characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy AT zhangqi characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy AT zhaoqiongrui characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy AT liyi characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy |